Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.43 |
| ▸ | PGK2 | P07205 | 1/20 | 0.43 |
| ▸ | PGD | P52209 | 3/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.36 |
| ▸ | TPI1 | P60174 | 1/20 | 0.35 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26321988 | 0.80 | LPAR3 (0.42) | PGK1PGK2PGDLPAR3LPAR2 | |
| SCHEMBL157689 | 0.76 | TPI1 (0.48) | PGK1PGK2PGDMPITPI1 | |
| SCHEMBL14370338 | 0.74 | PGK1 (0.41) | PGK1PGK2PGDLPAR3LPAR2 | |
| SCHEMBL202466 | 0.73 | LPAR3 (0.43) | PGK1PGK2PGDLPAR3LPAR2 | |
| SCHEMBL2710223 | 0.73 | LPAR3 (0.43) | PGK1PGK2PGDLPAR3LPAR2 | |
| SCHEMBL1198793 | 0.71 | LPAR3 (0.46) | PGK1PGK2LPAR3LPAR2LPAR1 | |
| SCHEMBL22661363 | 0.71 | PGD (0.42) | PGK1PGK2PGDLPAR3LPAR2 | |
| Hydrochloric Acid SCHEMBL22189200 | 0.71 | LPAR3 (0.41) | PGK1PGK2PGDLPAR3LPAR2 | |
| SCHEMBL27566719 | 0.71 | LPAR3 (0.41) | PGK1PGK2PGDLPAR3LPAR2 | |
| SCHEMBL11675767 | 0.71 | LPAR3 (0.41) | PGK1PGK2PGDLPAR3LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160017374-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL PRODUCTION OF ISOPRENE | CALYSTA INC (US) | 2016-01-21 | — | — | US | claimed |
| EP-2964748-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL PRODUCTION OF ISOPRENE | Calysta, Inc. (US) | 2016-01-13 | — | — | EP | claimed |
| EP-2499253-B1 | MICROORGANISMS HAVING ENHANCED SUCROSE MUTASE ACTIVITY | SÜDZUCKER AG MANNHEIM OCHSENFURT (DE) | 2015-04-22 | — | — | EP | claimed |
| WO-2014138419-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL PRODUCTION OF ISOPRENE | Calysta Energy, Inc. (US) | 2014-09-12 | — | — | WO | claimed |
| US-20160017374-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL PRODUCTION OF ISOPRENE | CALYSTA INC (US) | 2016-01-21 | — | — | US | disclosed |
| EP-2964748-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL PRODUCTION OF ISOPRENE | Calysta, Inc. (US) | 2016-01-13 | — | — | EP | disclosed |
| WO-2014138419-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL PRODUCTION OF ISOPRENE | Calysta Energy, Inc. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-8170852-B2 | Data structures and methods for modeling Saccharomyces cerevisiae metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100280803-A1 | Compositions and Methods for Modeling Saccharomyces cerevisiae Metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-11-04 | — | — | US | disclosed |
| US-7608450-B2 | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics | WYETH (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080260776-A1 | Preparation of Salmonella Broad-Spectrum Vaccines | BUMANN DIRK | 2008-10-23 | — | — | US | disclosed |
| US-7332310-B2 | Mutant of homoserine dehydrogenase from Corynebacterium and DNA encoding thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-02-19 | — | — | US | disclosed |
| US-20060063224-A1 | Method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in an essential metabolic pathway | SCHECHTER ALAN M | 2006-03-23 | — | — | US | disclosed |
| EP-1066309-A4 | LIBRARIES OF EXPRESSIBLE GENE SEQUENCES | INVITROGEN CORP (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1066404-A4 | METHODS FOR PRODUCING LIBRARIES OF EXPRESSIBLE GENE SEQUENCES | INVITROGEN CORP (US) | 2004-04-07 | — | — | EP | disclosed |
| US-6677502-B1 | ISOLATED POLYNUCLEOTIDE COMPRISING NUCLEOTIDE SEQUENCE ENCODING POLYPEPTIDE HAVING GTP CYCLOHYDROLASE II/3,4-DIHYDROXY-2-BUTANONE-4-PHOSPHATE SYNTHASE ACTIVITY, OR ITS COMPLEMENT | E.I. DU PONT DE NEMOURS AND COMPANY | 2004-01-13 | — | — | US | disclosed |
| EP-1066404-A1 | METHODS FOR PRODUCING LIBRARIES OF EXPRESSIBLE GENE SEQUENCES | INVITROGEN CORPORATION (US) | 2001-01-10 | — | — | EP | disclosed |
| EP-1066309-A1 | LIBRARIES OF EXPRESSIBLE GENE SEQUENCES | INVITROGEN CORPORATION (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999051766-A1 | METHODS FOR PRODUCING LIBRARIES OF EXPRESSIBLE GENE SEQUENCES | INVITROGEN CORPORATION (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999051620-A1 | LIBRARIES OF EXPRESSIBLE GENE SEQUENCES | INVITROGEN CORPORATION (US) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080260776-A1 | Preparation of Salmonella Broad-Spectrum Vaccines | SAMM50, TLR5, WASHC5 | PGK1 4041/4885PGK2 3677/4885PGD 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.